Journal
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 16, Issue 8, Pages 670-683Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389201016666150505124037
Keywords
Bispecific antibody; antibody engineering; cancer; immunotherapy; clinical trials; T cells; NK cells; cell death
Funding
- Televie Luxembourg
- Recherche Cancer et Sang Foundation
- Recherches Scientifiques Luxembourg association
- Een Haerz fir kriibskrank Kanner association
- Action LIONS Vaincre le Cancer association
- National Research Foundation (NRF)
- Ministry of Education, Science & Technology (MEST) of Korea for the Tumor Microenvironment Global Core Research Center (GCRC) [2012-0001184]
- Brain Korea [BK21]
Ask authors/readers for more resources
Targeted cellular immunotherapy with bifunctional antibodies (bsAbs) has emerged as a promising therapeutic approach for cancer over the last two decades. Progress in antibody engineering has led to the generation of many different types of antibody-derived entities that display at least two binding specificities. Most bsAbs consist of large IgG-like proteins with multiple antigen-binding regions containing Fc parts or smaller entities without Fc. BsAbs have the potential to engage effector cells of the immune system, thereby overcoming some of the immune response escape mechanisms of tumor cells. Preclinical and clinical trials of various bsAb constructs have demonstrated impressive results in terms of immune effector cell retargeting and induction of efficient anti-tumor responses. This review provides an overview of the established bsAbs focusing on improvements in format and design as well as the mechanisms of action of the most promising candidates and describes the results of the most recent clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available